B-cell acute lymphocytic leukemia
Conditions
Interventions
pomalidomide group:pomalidomide 1mg/day
Sponsors
the Second Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosed adult acute B lymphocytic leukemia; 2. After allogeneic hematopoietic stem cell transplantation; 3. Flow cytometry, leukemia-specific fusion gene quantification, next-generation sequencing and other methods to detect minimal residual disease positive; 4. Aged 18-60 years old, male or female; 5. Hematopoietic reconstruction; 6. Patients without acute graft-versus-host disease of grade 2 or above, or chronic graft-versus-host disease with a score of more than 2 points after transplantation; 7. No serious infection and organ dysfunction after transplantation. 8. Voluntarily participate in the study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Morphology of bone marrow cells suggests relapse; 2. Impaired renal or hepatic function (defined as total bilirubin greater than or equal to 2.5 times the upper limit of normal (ULN), aspartate aminotransferase or alanine aminotransferase greater than or equal to 3.0 times ULN, estimated glomerular filtration The passing rate is less than or equal to 40ml/min); 3. Received other anti-tumor therapy within 28 days of the protocol treatment; 4. Received other immunomodulators after transplantation; 5. Past history of thrombotic diseases; 6. Hypersensitivity to the study drug or contraindications to the use of pomalidomide; 7. Poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year event-free survival;overall survival for 2 years;2-year cumulative recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2-year non-recurrent mortality;Incidence of acute and chronic graft versus host disease;Adverse Effects Rate; | — |
Countries
China
Contacts
Public ContactWang Lu, Kong Peiyan
the Second Affiliated Hospital of Army Medical University
Outcome results
None listed